ARANESP
As listed in the register: ARANESP
200 mcg · solution
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Darbepoetin Alfa
- Used in
- Blood, clotting and anaemia
- Made by
- Amgen Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ARANESP). It describes the substance, not this exact product.
Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-07
Safety of the active substance
From the US prescribing label for the same active substance (ARANESP). It describes the substance, not this exact product.
No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )].
- Aranesp is contraindicated in patients with: Uncontrolled hypertension [see Warnings and Precautions ( 5.3 )].
- Pure red cell aplasia (PRCA) that begins after treatment with Aranesp or other erythropoietin protein drugs [see Warnings and Precautions ( 5.6 )].
- Serious allergic reactions to Aranesp [see Warnings and Precautions ( 5.7 )].
- Uncontrolled hypertension ( 4 ) Pure red cell aplasia (PRCA) that begins after treatment with Aranesp or other erythropoietin protein drugs ( 4 ) Serious allergic reactions to Aranesp ( 4 )
The most frequently reported serious adverse reactions with Aranesp were hypertension and convulsions.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Amgen Canada Inc |
|---|---|
| Active substance | Darbepoetin Alfa |
| Used in | Blood, clotting and anaemia |
| Strength | 200 mcg |
| Form | solution |
| Classification | B03XA02 · Blood, clotting and anaemia |
| Route | intravenous, subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02391783 |
| DPD drug code | 87710 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
19 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution19 products
- 15 mcg
- 25 mcg
40 mcg2
40 mcg · 2 companies
- 60 mcg
100 mcg3
100 mcg · 3 companies
200 mcg4
200 mcg · 4 companies
- Amgen Canada Inc · this page
- Amgen Canada Inc
- Amgen Canada Inc
- Amgen Canada Inc
- 325 mcg
500 mcg6
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.